Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
In vitro profiling using microfluidic models has become increasingly utilized in the evaluation of medical devices over the last
30 years. To evaluate the unique flow properties of embolic products, bespoke in vitro microfluidic test systems have been
developed. A traditional issue associated with angiographic guided administration of embolic products has been visualizing
real-time vascular positioning post-delivery. This issue has been addressed with the development of novel radiopaque beads.
The fundamental physiochemical properties of these novel embolic agents have been presented by Duran et al in 2016. However
the flow properties and user handling considerations have not been fully compared to non-radiopaque embolics in vitro. This
presentation will focus on the characterization of novel radiopaque microspheres and the profiling methods that have aided
in their development. It will also cover the specific advantages provided clinically through extensive in vitro profiling of flow
distribution, CT visualization and deliverability studies compared to in vivo distribution data. The flow properties of RO
Bead in terms of final distal location have been shown to be comparable to DC Bead™ under a variety of in vitro tests and
in vivo models however physiochemical properties inherent to the radiopacity functionality have been shown to alter the
compressibility, suspension and inter-channel packing characteristics in vitro. These physical properties have not been shown
to influence the in vivo physical penetration end-points, administration user response or distribution pattern of representative
sizes of either embolic in vitro.
Marcus Caine is an Innovation Scientist at BTG. Initially focusing on analytical method development and validation, he is pursuing part-time PhD with the University of Southampton in Applied Biomimetic Microfluidics and focusing on the application of this project to advancing treatment in the field of interventional oncology and pulmonology.